The global health burden of infection-associated cancers in the year 2002

International Journal of Cancer

Volumn 118, Issue 12, 2006, Pages 3030-3044

  Parkin, Donald Maxwell ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Attributable fraction; Cancer; Estimates; Infection

Indexed keywords

ARTICLE; BILE DUCT CARCINOMA; BLADDER CARCINOMA; BURKITT LYMPHOMA; CANCER; CANCER RISK; DEVELOPING COUNTRY; EPSTEIN BARR VIRUS; FASCIOLA HEPATICA; GEOGRAPHIC DISTRIBUTION; HELICOBACTER PYLORI; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HODGKIN DISEASE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS 1; INFECTION; KAPOSI SARCOMA; LIVER CANCER; LIVER CELL CARCINOMA; NASOPHARYNX CARCINOMA; NONHODGKIN LYMPHOMA; PREVALENCE; PRIORITY JOURNAL; SCHISTOSOMA HEMATOBIUM; STOMACH CARCINOMA; T CELL LYMPHOMA; UTERINE CERVIX CANCER; WART VIRUS;

AFRICA; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMERICAS; ANIMALS; ASIA; CHOLANGIOCARCINOMA; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; EPSTEIN-BARR VIRUS INFECTIONS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HEPATITIS B; HEPATITIS C; HUMANS; INFECTION; LYMPHOMA; NEOPLASMS; OPISTHORCHIASIS; OPISTHORCHIS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; SARCOMA, KAPOSI; SCHISTOSOMA HAEMATOBIUM; SCHISTOSOMIASIS; STOMACH NEOPLASMS; TUMOR VIRUS INFECTIONS; WORLD HEALTH;

EID: 33646413672     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21731     Document Type: Article

References (153)

1. Parkin DM, Pisani P, Muñoz N, and Ferlay J. The global health burden of infection associated cancers. In: Weiss RA, Beral V, Newton R, eds. Infections and human cancer. Cancer surveys, vol 33. New York: Cold Spring Harbor Laboratory Press, 1999.5-33.
2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0. Lyon: IARCPress, 2004.
3. Mueller NE, Birmann B, Parsonnet J, Schiffman M, Stuver S. Infectious agents. In: Schottenfeld D, Fraumeni JF, Jr, eds. Cancer epidemiology and prevention, 3rd ed. 2005. New York: Oxford University Press.
4. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, eds. Cancer incidence in five continents, vol. VIII, IARC Scientific Publications No. 155. Lyon, France: IARC, 2002.
5. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000;92:1823-30.
6. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EJ, Edwards BK, eds. SEER cancer statistics review, 1975-2001, 2004. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2001/.
7. UNAIDS 2004 Country-specific HIV and AIDS estimates and data, end 2003 (UNAIDS, July 2004). http://www.unaids.org/epidemic_update/ report/index.html.
8. Sriplung H, Parkin DM. Trends in the incidence of acquired immunodeficiency syndrome-related cancers in Thailand. Cancer 2004;101: 2660-6.
9. Cole P, MacMahon B. Attributable risk percent in case-control studies. Brit J Prev Soc Med 1971;25:242-4.
10. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
11. IARC monographs on the evaluation of carcinogenic risks to humans. Schistosomes, liver flukes and helicobacter pylori, vol. 61. Lyon: IARC, 1994.
12. Mégraud F, Brassens-Rabbé MP, Denis F, Belbouri A, Hoa DQ. Seroepidemiology of Campylobacter pylori infection in various populations. J Clin Microbiol 1989;27:1870-3.
13. Eurogast Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet 1993;341:1329-62.
14. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case-control studies nested within prospective cohorts. Gut 2001;49:347-53.
15. Everhart JE. Recent developments in the epidemiology of Helicobacter pylori. Gastroenterol Clinics of. N America 2002;29:559-78.
16. Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 2000;22:283-97.
17. Go MF. Natural history and epidemiology of Helicobacter pylori infection. Alim Pharm Ther 2002;16:3-15.
18. Wang KJ, Wang RT. [Meta-analysis on the epidemiology of Helicobacter pylori infection in China] Zhonghua Liu Xing Bing Xue Za Zhi 2003;24:443-6.
19. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-4.
20. Huang J-Q, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169-79.
21. Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 1999;94:2373-9.
22. Danesh J. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment Pharmacol Ther 1999;13:851-6.
23. Ekstrom AM, Signorello LB, Hansson LE, Bergstrom R, Lindgren A, Nyren O. Evaluating gastric cancer misclassification: a potential explanation for the rise in cardia cancer incidence. J Natl Cancer Inst 1999;91:786-90.
24. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelman JH, Friedman GD. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994;330:1267-71.
25. Newton R, Ferlay J, Beral V, Devesa SS. The epidemiology of non-Hodgkin's lymphoma: comparison of nodal and extra-nodal sites. Int J Cancer 1997;72:923-30.
26. IARC monographs on the evaluation of carcinogenic risks to humans. Human papillomaviruses, vol. 90. Lyon: IARC, 2005.
27. Daling JR, Madeleine MM, Schwartz SM, Shera KA, Carter JJ, McKnight B, Porter PL, Galloway DA, McDougall JK, Tamimi H. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 2002;84:263-70.
28. Madeleine MM, Daling JR, Carter JJ, Wipf GC, Schwartz SM, McKnight B, Kurman RJ, Beckmann AM, Hagensee ME, Galloway DA. Cofactors with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst 1997;89:1516-23.
29. Herrero R, Munoz N. Human papillomavirus and cancer. In: Weiss RA, Beral V, Newton R, eds. Infections and human cancer. Cancer surveys, vol. 33.: New York: Cold Spring Harbor Laboratory Press, 1999. 75-98.
30. Trimble CL, Hildesheim A, Brinton LA, Shah KV, Kurman RJ. Heterogeneous etiology of squamous carcinoma of the vulva. Obstet Gynecol 1996;87:59-64.
31. Frisch M, Fenger C, van den Brule AJC, Sørensen P, Meijer CJLM, Walboomers JMM, Adami H-O, Melbye M, Glimelius B. Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomaviruses. Cancer Res 1999;59:753-7.
32. Bezerra AL, Lopes A, Landman G, Alencar GN, Torloni H, Villa LL. Clinicopathologic features and human papillomavirus DNA prevalence of warty and squamous cell carcinoma of the penis. Am J Surg Patho. 2001;25:673-8.
33. Rubin MA, Kleter B, Zhou M, Ayala G, Cubilla AL, Quint WGV, Pirog EC. Detection and typing of human papillomavirus dna in penile carcinoma. Am J Pathol 2001;159:1211-8.
34. Shah KV. Do human papillomavirus infections cause oral cancer? J Natl Cancer Inst 1998;90:1585-6.
35. Franceschi S, Muñoz N, Snijders PJ, Walboomers WW. Human papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence. Cancer Epidemiol Biomarkers Prev 1996;5:567-75.
36. Snijders PJF, Steenbergen RDM, Meijer CJLM, Walboomers JMM. Role of human papillomaviruses in cancer of the respiratory and upper digestive tract. Clin Dermatol 1997;15:415-25.
37. Gillison ML, Shah KV. Human papillomavirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for HPV in a subset of head and neck cancers. Curr Opin Oncol 2001;13:183-8.
38. Herrero R, Castellsagué X, Pawlita M, Lissowska J, Kee F, Balaram P, Rajkumar T, Sridhar H, Rose B, Pintos J, Fernandez L, Idris A, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003; 95:1772-83.
39. van Houten VMM, Snijders PJF, van den Brekel MWM, Kummer JA, Meijer CJLM, van Leeuwen B, Denkers F, Smeele LE, Snow GB, Brakenhoff RH. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer 2001;93:232-5.
40. IARC monographs on the evaluation of carcinogenic risks to humans. Hepatitis Viruses, vol. 59. Lyon: IARC, 1994.
41. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004;38(Suppl 10):S158-68.
42. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347-54.
43. Shi J, Zhu L, Liu S, Xie WF. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer 2005;92:607-12.
44. Kuper HE, Tzonou A, Kaklamani E, Hadziyannis S, Tasopoulos N, Lagiou P, Trichopoulos D, Stuver S. Hepatitis B and C viruses in the etiology of hepatocellular carcinoma; a study in Greece using third-generation assays. Cancer Causes Control 2000;11:171-5.
45. Sun CA, Wu DM, Lin CC, Lu SN, You SL, Wang LY, Wu MH, Chen CJ. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 2003;157:674-82.
46. Kirk GD, Lesi OA, Mendy M, Akano AO, Sam O, Goedert JJ, Hainaut P, Hall AJ, Whittle H, Montesano R. The gambia liver cancer study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 2004;39:211-9.
47. WHO: hepatitis C-Global prevalence (update). Weekly Epidemiological Record No 49, Dec 1999. 425-7.
48. Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis 2002;2: 293-302.
49. Walter SD. Effects of interactions, confounding and observational error on attributable risk estimation. Amer J Epidemiol 1983;171: 598-604.
50. IARC monographs on the evaluation of carcinogenic risks to humans. Infections with Epstein-Barr virus and human herpes viruses, vol. 70. Lyon: IARC, 1997
51. de-The G, Geser A, Day NE, Tukei PM, Williams EH, Beri DP, Smith PG, Dean AG, Bronkamm GW, Feorino P, Henle W. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature 1978;274: 756-61.
52. Magrath I. The pathogenesis of Burkitt's lymphoma. Adv Cancer Res 1990;53:133-270.
53. Evans AS, Müeller NE. Virus and cancer. Causal Associations Ann Epidemiol 1990;1:71-92.
54. Lenoir GM, Philip T, Sohier R. Burkitt-type lymphoma: EBV association and cytogenetic markers in cases from various geographic locations. In: Magrath IT, O'Conor GT, Ramot B, eds. Pathogenesis of leukaemias and lymphomas: environmental influences, progress in cancer research and therapy, vol. 27. Raven Press: New York, 1984. 283-96.
55. Gutierrez MI, Bhatia K, Barriga F, Diez B, Muriel FS, de Andreas ML, Epelman S, Risueno C, Magrath IT. Molecular epidemiology of Burkitt's lymphoma from South America: differences in breakpoint location and Epstein-Barr virus association from tumors in other world regions. Blood 1992;79:3261-6.
56. Niedobitek G, Meru N, Delecluse HJ. Epstein-Barr virus infection and human malignancies. Int J Exp Pathol 2001;82:149-70.
57. Coté TR, Biggar RJ, Rosenberg PS, Devesa SS, Percy C, Yellin FJ, Lemp G, Hardy C, Geodert JJ, Blattner WA. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 1997;73:645-50.
58. Evans AS, Gutensohn NM. A population-based case control study of EBV and other viral antibodies among persons with Hodgkin's disease and their siblings. Int J Cancer 1984;34:147-57.
59. Mueller N, Evans A, Harris NL, Comstock GW, Jellum E, Magnus K, Orentreich N, Polk BF, Vogelman J. Hodgkin's Disease and Epstein-Barr Virus. Altered antibody pattern before diagnosis. New Engl J Med 1989;320:689-95.
60. Weiss LM, Movahed LA, Wamke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. New Engl J Med 1989;320:502-6.
61. Armstrong AA, Weiss LM, Gallagher A, Jones DB, Krajewski AS, Angus B, Brown G, Jack AS, Wilkins BS, Onions DE, et al. Criteria for the definition of Epstein-Barr virus association in Hodgkin's disease. Leukemia 1992;6:869-74.
62. Weinreb M, Day PJR, Niggli F, Powell JE, Raafat F, Hesseling PB, Schneider JW, Hartley PS, Tzortzatou-Stathopoulou F, Khalek ER, Mangoud A, El-Safy UR, et al. The role of Epstein-Barr virus in Hodgkin's disease from different geographical areas. Arch Dis Child 1996;74:27-31.
63. Jarrett RF, Gallagher A, Jones DB, Alexander FE, Krajewski AS, Kelsey A, Adams J, Angus B, Gledhill S, Wright DH, et al. Detection of Epstein-Barr virus genomes in Hodgkin's disease: relation to age. J Clin Pathol 1991;44:844-8.
64. Gledhill S, Gallagher A, Jones DB, Krajewski AS, Alexander FE, Klee E, Wright DH, O'Brien C, Onions DE, Jarrett RF. Viral involvement in Hodgkin's disease: detection of clonal type A Epstein-Barr virus genomes in tumour samples. Brit J Cancer 1991;64:227-32.
65. Glaser SL, Lin RJ, Stewart SL, Ambinder RF, Jarrett RF, Brousset P, Pallesen G, Gulley ML, Khan G, O'Grady J, Hummel M, Preciado MV, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer 1997;70: 375-82.
66. Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002;12:421-9.
67. de Thé G, Ho JH, Ablashi DV, Day NE, Macario AJ, Martin-Berthelon MC, Pearson G, Sohier R. Nasopharyngeal carcinoma. IX. Antibodies to EBNA and correlation with response to other EBV antigens in Chinese patients. Int J Cancer 1975;16:713-21.
68. Chen JY, Chen CJ, Liu MY, Cho SM, Hsu MM, Lynn TC, Shieh T, Tu SM, Beasley RP, Hwang LY, et al. Antibody to Epstein-Barr virus-specific DNase as a marker for field survey of patients with nasopharyngeal carcinoma in Taiwan. J Med Virology 1989;27:269-73.
69. Zheng X, Yan L, Nilsson B, Eklund G, Drettner B. Epstein-Barr virus infection, salted fish and nasopharyngeal carcinoma. Acta Oncologia 1994;33:867-72.
70. Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ, Yang CS. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. New Engl J Med 2001;345: 1877-82.
71. Pathmanathan R, Prasad U, Chandrika G, Sadler R, Flynn K, Raab-Traub N. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol 1995;146:1355-67.
72. IARC monographs on the evaluation of carcinogenic risks to humans. Human immunodeficiency viruses and human T-cell lymphotropic viruses, vol. 67. Lyon: IARC, 1996.
73. Centers for Disease Control: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Rep 1992;41:1-19.
74. Goedert JJ, Coté TR, Virgo P, Scoppa SM, Kingma DW, Gail MH, Jaffe ES, Biggar RJ. Spectrum of AIDS-associated malignant disorders. Lancet 1998;351:1833-39.
75. Frisch M, Biggar RJ, Engels EA, Goedert JJ, AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001;285:1736-45.
76. Grulich AE, Li Y, McDonald A, Correl PK, Law MG, Kaldor JM. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002;16:11-61.
77. Boshoff C, Weiss RA. Epidemiology and pathogenesis of Kaposi's sarcoma-associated herpesvirus. Phil Trans Roy Soc Lond B 2001; 356:517-34.
78. Ablashi D, Chatlynne L, Cooper H, Thomas D, Yadav M, Norhanom AW, Chandana AK, Churdboonchart V, Kulpradist SA, Patnaik M, Liegmann K, Masood R, et al. Seroprevalence of human herpesvirus-8 (HHV-8) in countries of Southeast Asia compared to the USA, the Caribbean and Africa. Br J Cancer 1999;81:893-7.
79. Schulz TF, Sheldon J, Greensill J. Kaposi's sarcoma associated herpesvirus (KSHV) or human herpes virus 8 (HHV 8). Virus Res 2002; 82:115-26.
80. Oettlé AG. Geographical and racial differences in the frequency of Kaposi's sarcoma as evidence of environmental or genetic causes. Acta Unio Int Contra Cancrum 1962;18:330-63.
81. Templeton AC. Kaposi's sarcoma. In: Sommers SC, Rosen PP, eds. Pathology annual. New York: Appleton Century-Crofts, 1981. 315-36
82. Serraino D, Pezzotti P, Dorrucci M, Alliegro MB, Sinicco A, Rezza G. Cancer incidence in a cohort of human immunodeficiency virus seroconverters: HIV Italian seroconvertion study group. Cancer 1997; 79:1004-8.
83. Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990;335:123-8.
84. Casabona J, Melbye M, Biggar RJ, the AIDS Registry Contributors. Kaposi's sarcoma and non-Hodgkin's lymphoma in European AIDS cases. Int J Cancer 1991;47:49-53.
85. Hoover DR, Black C, Jacobson LP, Martinez-Maza O, Seminara D, Saah A, Von Roenn J, Anderson R, Armenian HK. Epidemiologic analysis of Kaposi's sarcoma as an early and later AIDS outcome in homosexual men. Am J Epidemiol 1993;138:266-78.
86. Lundgren JD, Melbye M, Pedersen C, Rosenberg PS, Gerstoff J. Changing patterns of Kaposi's sarcoma in Danish acquired immunodeficiency syndrome patients with complete follow-up. Am J Epidemiol 1995;141:652-8.
87. Wabinga HR, Parkin DM, Wabwire-Mangen F, Nambooze S. Trends in cancer incidence in Kyandondo County, Uganda, 1969-1977. Brit J Cancer 2000;82:1585-92.
88. Chokunonga E, Levy LM, Basset MT, Borok MZ, Mauchaza BG, Chirenje MZ, Parkin DM. AIDS and cancer in Africa: the evolving epidemic in Zimbabwe. AIDS 1999;13:2583-8.
89. Clumeck N, Sonnet J, Taelman H, Mascart-Lemone F, De Bruyere M, Vandeperre P, Dasnoy J, Marcelis L, Lamy M, Jonas C, et al. Acquired immunodeficiency syndrome in African patients. New Engl J Med 1984;310:492-7.
90. Piot P, Quinn TC, Taelman H, Feinsod FM, Minlangu KB, Wobin O, Mbendi N, Mazebo P, Ndangi K, Stevens W, et al. Acquired immunodeficiency syndrome in a heterosexual population in Zaire. Lancet 1984;2:65-9.
91. Van de Perre P, Rouvroy D, Lepage P, Bogaerts J, Kestelyn P, Kayihigi J, Hekker AC, Butzler JP, Clumeck N. Acquired immunodeficiency syndrome in Rwanda. Lancet 1984;2:62-5.
92. Wabinga HR, Parkin DM, Wabwire-Mangen F, Mugerwa JW. Cancer in Kampala, Uganda, in 1989-91: changes in incidence in the era of AIDS. Int J Cancer 1993;54:26-36.
93. Ziegler JL, Drew WL, Miner RC, Mintz L, Rosenbaum E, Gershow J, Lennette ET, Greenspan J, Shillitoe E, Beckstead J, Casavant C, Yamamoto K. Outbreak of Burkitt's-like lymphoma in homosexual men. Lancet 1982;2:631-3.
94. Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet 1991;337:805-9.
95. Serraino D, Franchesi S, Tirelli U, Monfardini S. Epidemiology of acquired immunodeficiency syndrome and associated tumor in Europe Ann Oncol 1992;3:595-603.
96. Newton R, Grulich A, Beral V, Sindikubwabo B, Ngilimana PJ, Nganyira A, Parkin DM. Cancer and HIV infection in Rwanda. Lancet 1995;345:1378-9.
97. Sitas F, Bezwoda WR, Levin V, Ruff P, Kew MC, Hale MJ, Carrera H, Beral V, Fleming G, Odes R, Weaving A. Association between human immunodeficiency virus type 1 infection and cancer in the black population of Johannesburg and Soweto, South Africa. Brit J Cancer 1997;75:1704-7.
98. Sitas F, Pacella-Norman R, Carrara H, Patel M, Ruff P, Sur R, Jentsch U, Hale M, Rowji P, Saffer D, Connor M, Bull D, et al. The spectrum of HIV-1 related cancers in South Africa. Int J Cancer 2000;88:489-92.
99. Parkin DM, Garcia-Giannoli H, Raphael M, Martin A, Katangole-Mbidde E, Wabinga H, Ziegler J. Non-Hodgkin's lymphoma in Uganda: a case-control study. AIDS 2000;14:2929-36.
100. Mbulaiteye SM, Katabira ET, Wabinga H, Parkin DM, Virgo P, Ochai R, Workneh M, Coutinho A, Engels EA. Spectrum of cancers among HIV-infected persons in Africa: The Uganda AIDS-Cancer Match Registry Study. Int J Cancer 2005; Aug 16 ([pub ahead of print]).
101. Lucas SB, Diomande M, Hounnou A, Beaumel A, Giordano C, Kadio A, Peacock CS, Monde M, de Cock KM. HIV associated lymphoma in Africa: an autopsy study in Cote d'Ivoire. Int J Cancer 1994;59:20-4.
102. Hamilton-Dutoit SJ, Raphael M, Audouin J, Diebold J, Lisse I, Pedersen C, Oksenhendler E, Marelle L, Pallesen G. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. Blood 1993;82:619-24.
103. Dal Maso L, Serraino D, Franceschi S. Epidemiology of AIDS-related tumours in developed and developing countries. Eur J Cancer 2001; 37:1188-201.
104. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000;92: 1500-10.
105. Parkin DM, Ferlay J, Hamdi-Chérif M, Sitas F, Thomas JO, Wabinga H, Whelan SL, eds. Cancer in Africa: epidemiology and prevention. IARC Scientific Publications No. 153. Lyon, France: IARC, 2003.
106. Goedert JJ, Coté TR. Conjunctival malignant disease with AIDS in USA. Lancet 1995;2:257-8.
107. Mustacchi P, Shimkim MB. Cancer of the bladder and infestation with Schistosomahaematobium. J Natl Cancer Inst 1958;20:825-41.
108. Gelfand M, Weinberg RW, Castle WM. Relationship between carcinoma of the bladder and infestation with Schistosoma haematobium. Lancet 1967;1:1249-51.
109. Elem B, Purohit R. Carcinoma of the urinary bladder in Zambia. A quantitative estimation of Schistosoma haematobium infection. Brit J Urology 1983;55:275-8.
110. Vizcaino AP, Parkin DM, Boffetta P, Skinner MEG. Bladder cancer: epidemiology and risk factors in Bulawayo, Zimbabwe. Cancer Causes Control 1994;5:517-22.
111. Bedwani R, Renganathan E, El Kwhsky F, Braga C, Abu Seif HH, Abul Azm T, Zaki A, Franceschi S, Boffetta P, La Vecchia C. Schistosomiasis and the risk of bladder cancer in Alexandria, Egypt. Brit J Cancer 1998;77:1186-9.
112. Utroska JA, Chen MG, Dixon H, Yoon S, Helling-Borda M, Hogerzeil HV, Mott KE. An estimate of global needs for praziquantel within Schistosomiasis control programmes. WHO/SCHISTO/89.102. Division of Control of Tropical Diseases, WHO, Geneva. 1989.
113. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult cell leukaemia: clinical and hematologic features of 16 cases. Blood 1977;50:481-92.
114. Yoshida M, Hattori S, Seiki M. Molecular biology of human T-cell leukaemia. In: Voigt P, ed. Current topics in microbiology and immunology, vol. 5. Berlin: Springer, 1985. Curr Top Microbiol Immunol, 1985;115:157-75.
115. Blattner WA, Blayney DW, Robert-Guroff M, Sarngadharan MG, Kalyanaraman VS, Sarin PS, Jaffe ES, Gallo RC. The epidemiology of human T-cell leukaemia/lymphoma virus. J Inf Dis 1983;147:406-16.
116. Tajima K, Hinuma Y. Epidemiology of HTLV I/II in Japan and the world. Gann monograph on cancer research (Japanese). J Cancer Res 1992;39:129-49.
117. Verdier M, Bonis M, Denis FA. The prevalence and incidence of HTLVs in Africa. In: Essex M, Mboup S, Karhi PJ, Kalengayi MR. AIDS in Africa. New York: Raven Press, 1984.173-93.
118. Kondo T, Kono H, Miyamoto N, Yoshida R, Toki H, Matsumoto I, Hara M, Inoue H, Inatsuki A, Funatsu T, et al. Age- and sex-specific cumulative rate and risk of ATLL for HTLV-I carriers. Int J Cancer 1989;43:1061-4.
119. Tajima K, Kuroishi T. Estimation of incidence rate of ATL among ATLV carriers in Kyushu, Japan (Japanese). J Clin Oncol 1985;15: 423-30.
120. Tokudome S, Tokunaga O, Shimamoto Y, Miyamoto Y, Sumida I, Kikuchi M, Takeshita M, Ikeda T, Fujiwara K, Yoshihara M, et al. Incidence of adult T-cell leukaemia/lymphoma among human T-lymphotropic virus type I carriers in Saga (Japanese). Cancer Res 1989; 49:226-8.
121. Arisawa K, Soda M, Endo S, Kurokawa K, Katamine S, Shimokawa I, Koba T, Takahashi T, Saito H, Doi H, Shirahama S. Evaluation of adult T-cell leukemia/lymphoma incidence and its impact on non-Hodgkin ymphoma incidence in southwe stern Japan. Int J Cancer 2000;85:319-24.
122. Murphy EL, Hanchard B, Figueroa JP, Gibbs WN, Lofters WS, Campbell M, Goedert JJ, Blattner WA. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer 1989;43:250-3.
123. Cleghorn FR, Manns A, Falk R, Hartge P, Hanchard B, Jack N, Williams E, Jaffe E, White F, Bartholomew C, et al. Effect of human T-lymphotropic virus type I infection on non-Hodgkin's lymphoma incidence. J Natl Cancer Inst 1995;87:1009-14.
124. Levine PH, Blattner WA. The epidemiology of human virus associated haematologic maligancies. Leukemia. 1992;6(Suppl 3):54S-59S.
125. Parkin DM, Srivatanakul P, Khlat M, Chenvidhya D, Chotiwan P, Insiripong S, L'Abbe KA, Wild CP. Liver cancer in Thailand. I. A case-control study of cholangiocarcinoma. Int J Cancer 1991;48:323-8.
126. Haswell-Elkins MR, Mairiang E, Mairiang P, Chaiyakum J, Chamadol N, Loapaiboon V, Sithithaworn P, Elkins DB. Cross-sectional study of Opisthorchis viverrini infection and cholangiocarcinoma in communities within a high-risk area in northeast Thailand. Int J Cancer 1994;59:505-9.
127. Honjo S, Srivatanakul P, Sriplung H, Kikukawa H, Hanai S, Uchida K, Todoroki T, Jedpiyawongse A, Kittiwatanachot P, Sripa B, Deerasamee S, Miwa M. Genetic and environmental determinants of risk for cholangiocarcinoma via Opisthorchis viverrini in a densely infested area in Nakhon Phanom, northeast Thailand. Int J Cancer 2005;117:854-60.
128. Chung CS, Lee SK. An epidemiological study of primary liver carcinomas in Pusan area with special reference to clonorchiasis (Korean). J Pathology 1976;10:33-46.
129. Shin HR, Lee CU, Park HJ Seol SY, Chung JM, Choi HC, Ahn YO, Shigemastu T. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol 1996;25:933-40.
130. Parkin DM, Ohshima H, Srivatanakul P, Vatanasapt V. Cholangiocarcinoma: epidemiology, mechanisms of carcinogenesis and prevention. Cancer Epidemiol Biomarkers Prev 1993;2:537-44.
131. WHO Control of Food borne trematode infections. WHO Technical Report Series No 849, WHO Geneva, 1995.
132. Herrmann K, Niedobitek G. Epstein-Barr virus-associated carcinomas: facts and fiction. J Pathol 2003;199:140-5.
133. Takada K. Epstein-Barr virus and gastric carcinoma. Mol Pathol 2000;53:255-61.
134. [34. Levine PH, Stemmermann G, Lennette ET, Hildesheim A, Shibata D, Nomura A. Elevated antibody titers to Epstein-Barr virus prior to the diagnosis of Epstein-Barr-virus-associated gastric adenocarcinoma. Int J Cancer 1995;60:642-4.
135. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma:systematic review and meta-analysis. Gastroenterology 2003;125:1723-32.
136. Negri E, Little D, Boiocchi M, La Vecchia C, Franceschi S. B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer 2004;111:1-8.
137. Smith JS, Bosetti C, Munoz N, Herrero R, Bosch FX, Eluf-Neto J, Meijer CJ, Van Den Brale AJ, Franceschi S, Peeling RW. IARC multicentric case-control study. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer 2004;111:431-9.
138. Paterlini P, Gerken G, Nakajima E, Terre S, D'Errico A, Grigioni W, Nalpas B, Franco D, Wands J, Kew M, et al. Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. N Engl J Med 1990;323:80-5.
139. Brenner H, Arndt V, Stegmaier C, Ziegler H, Rothenbacher D. Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer? Am J Epidemiol 2004;159:252-8.
140. The Gambia Hepatitis Intervention Study (GHIS). The Gambia Hepatitis Study Group. Cancer Res 1987;47:5782-7.
141. Sun Z, Zhu Y, Stjernsward J, Hilleman M, Collins R, Zhen Y, Hsia CC, Lu J, Huang F, Ni Z, et al. Design and compliance of HBV vaccination trial on newborns to prevent hepatocellular carcinoma and 5-year results of its pilot study. Cancer Detect Prev 1991;15:313-8.
142. World Health Organization (WHO). Immunization surveillance, assessment and monitoring. http://www.who.int/immunization_monitoring/ en/ (Accessed October 2005).
143. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Child-hood Hepatoma Study Group. N Engl J Med 1997;336:1855-9.
144. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
145. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364: 1757-65.
146. Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CA, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
147. Skjeldestad FE. Prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine (Gardasil(tm)) reduces cervical intraepithelial neoplasia (CIN) 2/3 risk. Presented at the 2005 meeting of the Infectious Diseases Society of America. San Francisco, CA. Abstract LB-8a.
148. Muñoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85.
149. Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996;348:150-4.
150. Mason J, Axon AT, Forman D, Duffett S, Drummond M, Crocombe W, Feltbower R, Mason S, Brown J, Moayyedi P. Leeds HELP Study Group. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment Pharmacol Ther 2002;16:559-68.
151. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291: 187-94.
152. Parsonnet J, Forman D. Helicobacter pylori infection and gastric cancer-for want of more outcomes. JAMA 2004;291:244-5.
153. United Nations (2003) World population prospects. The 2002 revision. Population database. http://esa.un.org/unpp/.